Request Demo

Last update 23 Jan 2025

Alveolar Bone Loss

Last update 23 Jan 2025

Basic Info

Synonyms

Alveolar Bone Atrophies, Alveolar Bone Atrophy, Alveolar Bone Loss

+ [32]

Introduction

Resorption or wasting of the tooth-supporting bone (ALVEOLAR PROCESS) in the MAXILLA or MANDIBLE.

Drugs associated with Alveolar Bone Loss

DWP-431

Target

BMPR1A x BMPR1B

Mechanism

BMPR1A stimulants [+1]

Active Org.

Daewoong Pharmaceutical Co., Ltd.

Originator Org.

Daewoong Pharmaceutical Co., Ltd.

Active Indication

Alveolar Bone Loss [+1]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

South Korea

First Approval Date25 Jun 2014

Trafermin

Target

FGFRs

Mechanism

FGFRs stimulants

Active Org.

Kaken Pharmaceutical Co., Ltd.

Originator Org.

Kaken Pharmaceutical Co., Ltd.

Active Indication

Periodontitis [+2]

Inactive Indication

Alveolar Bone Loss [+2]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

Japan

First Approval Date04 Apr 2001

Ixmyelocel-T (Vericel)

Target-

Mechanism

Cell replacements

Active Org.-

Originator Org.

Vericel Corp.

Active Indication-

Inactive Indication

Alveolar Bone Loss [+9]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

433

Clinical Trials associated with Alveolar Bone Loss

RBR-9jw6tnm

/ Not yet recruitingNot ApplicableIIT

Barbell technique versus titanium reinforced PTFE membranes for bidirectional bone augmentation: multi-centre randomized clinical trial study

Start Date01 Feb 2025

Sponsor / Collaborator-

ChiCTR2400094775

/ RecruitingEarly Phase 1IIT

Evaluation of the Clinical Effectiveness of Thermosensitive Hydroxybutyl Chitosan Loaded with Concentrated Growth Factors for Alveolar Bone Defect Repair Based on Real-World Data

Start Date01 Jan 2025

Sponsor / Collaborator

First Affiliated Hospital Of Fujian Medical University

NCT06676826

/ Not yet recruitingNot Applicable

Treatment of Periodontal Intra-bony Defects With a Volume Stable Collagen Matrix or Deproteinized Bovine Bone Mineral With 10% Collagen. A 12-month Multi-center Randomized Controlled Trial

To compare the healing of intrabony periodontal defects treated with either open flap debridement and a volume-stable collagen matrix (VCMX) or a deproteinized bovine bone mineral with 10% collagen. The results will shed light on the clinical potential of VCMX in regenerative periodontal surgery and help to develop new treatment strategies.

Start Date01 Jan 2025

Sponsor / Collaborator

University of Bern

100 Clinical Results associated with Alveolar Bone Loss

100 Translational Medicine associated with Alveolar Bone Loss

0 Patents (Medical) associated with Alveolar Bone Loss

1,863

Literatures (Medical) associated with Alveolar Bone Loss

01 Apr 2025·Colloids and Surfaces B: Biointerfaces

Gelatin methacryloyl @MP196/exos hydrogel induced neutrophil apoptosis and macrophage M2 polarization to inhibit periodontal bone loss

Article

Author: Zhang, Xi ; Wang, Hongbo ; Deng, Jiayin ; Zhang, Shuting ; Zhuo, Haiwei

OBJECTIVESPeriodontitis is an inflammatory and destructive disease caused by dental plaque, which can result in the immune microenvironment disorders and loss of periodontal support tissue. In order to promote the restoration of local microenvironment stability, a functional biomaterial Gelatin methacryloyl @MP196/exos based on characteristics of disease occurrence is designed.METHODSTransmission electron microscopy, nanosight particle tracking analysis and western blot analysis were applied to prove the presence of exos in GelMA@MP196/exos. The swelling and degradation rates of GelMA@MP196/exos were evaluated. Cell proliferation, antibacterial ability and cellular uptake and intracellular internalization of exos were assessed in the study. Efferocytosis and M2 polarization of macrophages was estimated and the effects of GelMA@MP196/exos were proved in vivo.RESULTSGelMA@MP196/exos upregulated the expression of genes and proteins related to neutrophil apoptosis and promoted neutrophil apoptosis, macrophage M2 polarization, and efferocytosis. Furthermore, GelMA@MP196/exos exhibited significant antibacterial activity against Streptococcus gordonii, Fusobacterium nucleatum, and Porphyromonas gingivalis. GelMA@MP196/exos alleviated periodontitis and reduced alveolar bone loss in vivo in rat models.CONCLUSIONSGelMA@MP196/exos can serve as a potential strategy for the treatment of periodontitis.CLINICAL SIGNIFICANCEThe main aim of periodontal therapy is to remove dental plaque and eliminate inflammation. However, some patients with low plaque scores and insufficient neutrophil clearance, resulting in poor responsiveness to periodontal therapy. Under the circumstances, local Application of drug that regulate the immune microenvironment had significance in controlling the progression of inflammation.

01 Mar 2025·Cellular Signalling

METTL3-mediated m6A modifications of NLRP3 accelerate alveolar bone resorption through enhancing macrophage pyroptosis

Article

Author: Huang, Xin ; Ma, Li ; Wang, Xiaoxuan ; Sun, Jiahui ; Xiao, Junhong ; Liu, Heyu ; Liu, Yuqi ; Cao, Zhengguo ; Wang, Chuan ; Wang, Huiyi ; Yang, Zhengkun ; Yang, Qiudong

Periodontitis (PD) is twice as prevalent in diabetics compared to nondiabetics, and diabetes-associated PD is characterized by increased inflammation and aggravated tissue damage. Pyroptosis has recently been implicated in diabetes-associated PD; however, the underlying mechanisms remain largely unknown, resulting in a lack of effective treatments. In this study, we investigated the role of methyltransferase-like 3 (METTL3) in macrophage pyroptosis and found that it inhibits the osteogenic differentiation of osteoblasts via pyroptotic macrophages in a diabetes-associated periodontitis mouse model. Further analysis and validation revealed that nod-like receptor family pyrin domain-containing 3 (NLRP3) is a target of METTL3, with its mRNA stability regulated through a binding of insulin-like growth factor 2 binding protein 3 (IGF2BP3)-dependent pathway. Additionally, local injection of adeno-associated virus 9 (AAV9) demonstrated that METTL3 deficiency in macrophages significantly ameliorates periodontal inflammation and alveolar bone loss in diabetes-associated PD mice. Collectively, our findings indicate that METTL3-mediated modulation of NLRP3 expression is a crucial factor in macrophage pyroptosis during diabetes-associated PD progression. This suggests that the METTL3/IGF2BP3/NLRP3 axis is a novel and promising target for the improvement of periodental inflammation and alveolar bone loss in diabetes-associated PD.

01 Feb 2025·Oral and Maxillofacial Surgery Clinics of North America

20 Years of Clinical Evolution in Zygomatic Implant Rehabilitation

Review

Author: Davó, Rubén ; Fan, Shengchi

Zygoma implants are an alternative for rehabilitating severe maxillary atrophy. Since 2004, when Prof. Branemark first reported the long-term findings on zygomatic implants using the original intra-sinus approach, various surgical techniques have been introduced. In 2006, an anatomy-guided approach was developed, applying different implant trajectories based on alveolar atrophy levels and sinus concavity. The purpose of this review is to clarify the existing techniques and long-term outcomes of ZI rehabilitation over the past 20 years. Additionally, it aims to enhance the quality of current practices and identify gaps in the understanding of ZI treatment for future studies.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Alveolar Bone Loss

Basic Info

Related

Analysis